TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Recovery of exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total work for repeated sprinting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spherical aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urinary CTX‐II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotic requirements on the second postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity from ointment application (headaches)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CoDG (Center of Gaze Direction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodynamic mobility changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in diagnostic skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean SBP decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life measured with the DLQI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: high-sensitivity troponin T (hs-TnT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pressure rate quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PD symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of onercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption rate constant of onercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of onercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPIC sexual domain-scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EPIC urinary incontinence domain-scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EDITS total-scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of emphysema progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Yearly FEV1 decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean daily reflective total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor restless behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of YAG capsulotomy for PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombotic event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to regain full consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery scores at 15, 30, 45 and 60 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemorrhage rate
Endpoint domain: Adverse events/effects
Primary endpoint: Gamma-glutamyl transpeptidase decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prescribing of NSAIDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak serum concentration of platinum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascitic fluid concentration of platinum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of leukopenia/neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Antimicrobial activity against S. mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antimicrobial activity against Candida spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Control of denture biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Interstitial Cystitis Symptom Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: empathy score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bifidobacteria concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hb level responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepcidin level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Musculoskeletal Pain (MSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ICARS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Insulin sensitivity index (IS(OGTT))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean haemoglobin rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: catch-up in weight/height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enteral caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T1, T2, and T2* tissue properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedure-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of Helicobacter pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Glucose infusion rate (M value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin sensitivity index (M/I ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: absolute value of the deviations at the centroid of the pedicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unacceptable breaches
Endpoint domain: Adverse events/effects
Primary endpoint: Tinnitus severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of pulmonary vein isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence of risperidone formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 neutropenia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: platinum dose intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of total rhinoconjunctivitis symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in New York Heart Association class III to IV symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion avoidance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BODE index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of distant disease
Endpoint domain: Mortality/survival
Primary endpoint: Histology of prostatectomy specimens revealing aggressive cancer characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite primary end point at seven days
Endpoint domain: Mortality/survival
Primary endpoint: Death or myocardial infarction at seven days
Endpoint domain: Mortality/survival
Primary endpoint: Required insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length of stay in hospital and ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Baseline concentrations of cholesterol esters (CEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of posterior-wall punctures
Endpoint domain: Adverse events/effects
Primary endpoint: Number of skin punctures
Endpoint domain: Adverse events/effects
Primary endpoint: Number of attempts to surmount the learning curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased TpTe/QT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased TpTe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammatory mediator levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of WHO grade 2 or higher oral mucositis (OM)
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate/severe pain during needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postinjection pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporary numbness/paresthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Serum gamma-tocopherol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative hypocalcemia frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced consumption of analgesic medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of the CTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum fructosamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pressor responsiveness (PD10 for ANGII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hypocalcemia
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma 1,25‐(OH)2D3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ONSD measurement success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-stage kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain visual analogue scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active flexion degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shock recovery time (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Health status improvement (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vasodilation to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total drainage blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of haematomas
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients cured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pancreatic β‐cell responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardiovascular hospitalizations or death
Endpoint domain: Mortality/survival
Primary endpoint: Cardiovascular hospitalizations alone
Endpoint domain: Mortality/survival
Primary endpoint: mean leakage weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: percentage of continent patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Stress coping pattern change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic thresholds for adrenergic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal responses for adrenergic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth of bacteria and viruses in cultures
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse-free time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the third stage of labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma-related quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients achieving HbA1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma glucose improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SBP decrease after CSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of symptom reporting after CSM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein carbonyl concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saliva flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amylase output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TVR at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: 3-year MI
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in total HAMD17 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HAMD17 Anxiety/Somatization Factor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average 24h heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total consumption of rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loneliness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Melancholy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freezing of gait episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step time variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step time asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural responding to rewarding stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural responding to aversive stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Pressure Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Airway wall thickness percentage (WT%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway remodeling assessment via MDCT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: shoulder joint stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hp-negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height gain at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height SDS at near-final height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trabecular BVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: trabecular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: trabecular AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: BPI worst pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPI pain right now
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSAS Psychological
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: nasal carriage of S. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: nasal carriage of NCHi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prediction of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BHR level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sputum eosinophil %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Partial tumor remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in cerebrovascular autoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STS (Secondary Trauma Stress)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SPTG (Secondary Post-Traumatic Growth)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients achieving ACR50 response at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mineral gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remineralizing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quit attempts at 1-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quit attempts at 3-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WRpeak during SRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRpeak during SRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2peak during SRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent reduction of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reduction of >or=50% of baseline proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: erythrocyturia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ICRS II score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of defect repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Th17 in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratios of Th17/Treg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum level of IL-17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CTTH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMA responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WMFT functional ability scores responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PMII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post-intensive care unit hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: total hospitalization costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of MAKE-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of unplanned visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of planned visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recovery of attention and executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Instrumental Activities of Daily Living (IADL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of apathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American College of Rheumatology 20% response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dropout rates
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in night vision disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes